Javascript must be enabled to continue!
Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum
View through CrossRef
The trace amine-associated receptor 1 (TAAR1) is a Gs protein-coupled, intracellularly located metabotropic receptor. Trace and classic amines, amphetamines, act as agonists on TAAR1; they activate downstream signal transduction influencing neurotransmitter release via intracellular phosphorylation. Our aim was to check the effect of the catecholaminergic activity enhancer compound ((−)BPAP, (R)-(−)-1-(benzofuran-2-yl)-2-propylaminopentane) on neurotransmitter release via the TAAR1 signaling. Rat striatal slices were prepared and the resting and electrical stimulation-evoked [3H]dopamine release was measured. The releaser (±)methamphetamine evoked non-vesicular [3H]dopamine release in a TAAR1-dependent manner, whereas (−)BPAP potentiated [3H]dopamine release with vesicular origin via TAAR1 mediation. (−)BPAP did not induce non-vesicular [3H]dopamine release. N-Ethylmaleimide, which inhibits SNARE core complex disassembly, potentiated the stimulatory effect of (−)BPAP on vesicular [3H]dopamine release. Subsequent analyses indicated that the dopamine-release stimulatory effect of (−)BPAP was due to an increase in PKC-mediated phosphorylation. We have hypothesized that there are two binding sites present on TAAR1, one for the releaser and one for the enhancer compounds, and they activate different PKC-mediated phosphorylation leading to the evoking of non-vesicular and vesicular dopamine release. (−)BPAP also increased VMAT2 operation enforcing vesicular [3H]dopamine accumulation and release. Vesicular dopamine release promoted by TAAR1 evokes activation of D2 dopamine autoreceptor-mediated presynaptic feedback inhibition. In conclusion, TAAR1 possesses a triggering role in both non-vesicular and vesicular dopamine release, and the mechanism of action of (−)BPAP is linked to the activation of TAAR1 and the signal transduction attached.
Title: Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum
Description:
The trace amine-associated receptor 1 (TAAR1) is a Gs protein-coupled, intracellularly located metabotropic receptor.
Trace and classic amines, amphetamines, act as agonists on TAAR1; they activate downstream signal transduction influencing neurotransmitter release via intracellular phosphorylation.
Our aim was to check the effect of the catecholaminergic activity enhancer compound ((−)BPAP, (R)-(−)-1-(benzofuran-2-yl)-2-propylaminopentane) on neurotransmitter release via the TAAR1 signaling.
Rat striatal slices were prepared and the resting and electrical stimulation-evoked [3H]dopamine release was measured.
The releaser (±)methamphetamine evoked non-vesicular [3H]dopamine release in a TAAR1-dependent manner, whereas (−)BPAP potentiated [3H]dopamine release with vesicular origin via TAAR1 mediation.
(−)BPAP did not induce non-vesicular [3H]dopamine release.
N-Ethylmaleimide, which inhibits SNARE core complex disassembly, potentiated the stimulatory effect of (−)BPAP on vesicular [3H]dopamine release.
Subsequent analyses indicated that the dopamine-release stimulatory effect of (−)BPAP was due to an increase in PKC-mediated phosphorylation.
We have hypothesized that there are two binding sites present on TAAR1, one for the releaser and one for the enhancer compounds, and they activate different PKC-mediated phosphorylation leading to the evoking of non-vesicular and vesicular dopamine release.
(−)BPAP also increased VMAT2 operation enforcing vesicular [3H]dopamine accumulation and release.
Vesicular dopamine release promoted by TAAR1 evokes activation of D2 dopamine autoreceptor-mediated presynaptic feedback inhibition.
In conclusion, TAAR1 possesses a triggering role in both non-vesicular and vesicular dopamine release, and the mechanism of action of (−)BPAP is linked to the activation of TAAR1 and the signal transduction attached.
Related Results
Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization
Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization
AbstractWe examined the effect of chronic nicotine treatment on dopaminergic activity by measuring the effects of D1 and D2 dopamine (DA) receptor agonists and antagonists on triti...
Targeting MYC-inducing enhancer-associated noncoding (MYC-IEANC) RNAs inhibits the proliferation of HCC cells
Targeting MYC-inducing enhancer-associated noncoding (MYC-IEANC) RNAs inhibits the proliferation of HCC cells
Abstract
Background
MYC, a critical oncogene, encodes the c-MYC transcription factor (TF) and plays an essential role in hepatocellular carcinoma (HCC) development. Recen...
Applications and implications of neurochemical biomarkers in environmental toxicology
Applications and implications of neurochemical biomarkers in environmental toxicology
Abstract
Thousands of environmental contaminants have neurotoxic properties, but their ecological risk is poorly characterized...
Probing Dopaminergic Modulation via Subthalamic Stimulation: A Preclinical Perspective
Probing Dopaminergic Modulation via Subthalamic Stimulation: A Preclinical Perspective
Introduction: Subthalamic nucleus (STN) deep brain stimulation (DBS) is currently the gold standard symptomatic treatment for patients with levodopa therapy-induced complications i...
The Juvenile Idiopathic Arthritis (JIA) Susceptibility Locus, IL2RA, Includes An Intronic Enhancer That Is Attenuated By JIA-Associated Genetic Variants
The Juvenile Idiopathic Arthritis (JIA) Susceptibility Locus, IL2RA, Includes An Intronic Enhancer That Is Attenuated By JIA-Associated Genetic Variants
Like most rheumatic diseases, genetic risk loci for juvenile idiopathic arthritis (JIA) are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic signatures often associate...
Developmental and housekeeping transcriptional programs display distinct modes of enhancer-enhancer cooperativity in
Drosophila
Developmental and housekeeping transcriptional programs display distinct modes of enhancer-enhancer cooperativity in
Drosophila
Abstract
Genomic enhancers are key transcriptional regulators which, upon the binding of sequence-specific transcription factors, activate their ...
Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
Selegiline and rasagiline are two selective monoamine oxidase B (MAO-B) inhibitors used in the treatment of Parkinson’s disease. In their clinical application, however, differences...
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease
New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease
Abstract
Alpha melanocyte-stimulating hormone (
α
-MSH) is an autocrine factor released by activated microgli...

